Prospecta in the Treatment of Cognitive, Behavioural and Psychiatric Disorders in Patients With Vascular Dementia.
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
Study purpose:
- evaluate safety and clinical efficacy of Prospecta in the treatment of cognitive,
behavioural and psychiatric disorders in patients with vascular dementia.
Study objectives:
- evaluate and compare changes in cognitive functions and in behavioural and psychiatric
dementia symptoms in Prospecta and Placebo groups after 24-week therapy:
- evaluate and compare the frequency, severity and causal relationship of adverse events
(AEs) with the type of therapy in Prospecta and Placebo groups (including central
nervous system AEs during therapy, their relationship with the product and other
characteristics).